TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31540966

Group type: EXPERIMENTAL
Intervention: RNA expression profiles analysis using RNAseq
Number of subjects: 417
Study: 31541068

Group type: EXPERIMENTAL
Intervention: Ecological Momentary Assessment (EMA)
Number of subjects: 45
Study: 31541204

Group type: EXPERIMENTAL
Intervention: Unrelated peripheral blood stem cell graft (PBSC) with PTCy, tacrolimus, and MMF
Number of subjects: 79

Group type: COMPARATOR
Intervention: Matched-related bone marrow (BM) grafts with single-agent PTCy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: High prevalence of CD3, NKT, and CD16-CD56+ subpopulations in PBSC grafts
Number of subjects: 79
Study: 31541293

Group type: EXPERIMENTAL
Intervention: Knee Control injury prevention exercise programme (IPEP) or Knee Control+
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 8
Study: 31541381

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle + trastuzumab every 3 weeks (Cohort 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle (Cohort 3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cabozantinib 60-mg daily on a 21-day cycle
Number of subjects: 36
Study: 31541945

Group type: EXPERIMENTAL
Intervention: Oral panobinostat plus chemotherapy (idarubicin and cytarabine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Idarubicin and cytarabine (chemotherapy)
Number of subjects: 0
Study: 31542380

Group type: EXPERIMENTAL
Intervention: EUS-guided nCLE characteristics of increased papillary epithelial width (cut-off ≥50 μm)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: EUS-guided nCLE characteristics of increased papillary epithelial darkness (cut-off ≤90 pixel intensity)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for width
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Interobserver agreement for darkness
Number of subjects: 26
Study: 31542526

Group type: EXPERIMENTAL
Intervention: Doxorubicin or doxorubicin followed by trastuzumab
Number of subjects: 362

Group type: COMPARATOR
Intervention: Trastuzumab alone
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Changes in E/e' ratio
Number of subjects: 362
Study: 31542729

Group type: EXPERIMENTAL
Intervention: Round facemasks with an external diameter of 50 mm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Round facemasks with an external diameter of 42 mm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Round facemasks with an external diameter of 60 mm
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 2D images
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 3D images
Number of subjects: 102
Study: 31542738

Group type: EXPERIMENTAL
Intervention: Polso National Early Warning Score measurements
Number of subjects: 300

Group type: COMPARATOR
Intervention: Manual measurements
Number of subjects: 300
Study: 31542743

Group type: EXPERIMENTAL
Intervention: Resilience and quality of life assessment using EORTC QLQ-C30, EORTC QLQ-H&N35, EORTC QLQ-BN20, and Wagnild and Young's 14-item scale.
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Correlation analysis using Pearson or Spearman rank correlation coefficients.
Number of subjects: 500
Study: 31543165

Group type: EXPERIMENTAL
Intervention: DCB
Number of subjects: 1069

Group type: COMPARATOR
Intervention: PTA
Number of subjects: 1069

Group type: EXPERIMENTAL
Intervention: DCB (propensity-matched)
Number of subjects: 1069

Group type: COMPARATOR
Intervention: PTA (propensity-matched)
Number of subjects: 1069
Study: 31543859

Group type: EXPERIMENTAL
Intervention: Progressive Modular Rebalancing System and Visual Cueing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31543982

Group type: EXPERIMENTAL
Intervention: Team-Based Goals and Incentives (TBGI) intervention
Number of subjects: 1300
Study: 31544065

Group type: EXPERIMENTAL
Intervention: Intrathecal Pemetrexed
Number of subjects: 0
Study: 31544817

Group type: EXPERIMENTAL
Intervention: MEDI4276 (antibody-drug conjugate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEDI1498 (de-acetylated MEDI4276)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEDI4276 and MEDI1498
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MEDI4276
Number of subjects: 0
Study: 31544944

Group type: COMPARATOR
Intervention: Transgender Males (TM)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Transgender Females (TF)
Number of subjects: 69
Study: 31544947

Group type: EXPERIMENTAL
Intervention: Treatment (surgery or medical treatment)
Number of subjects: 18
Study: 31545113

Group type: EXPERIMENTAL
Intervention: Selinexor in combination with decitabine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31545689

Group type: EXPERIMENTAL
Intervention: Reduced-dose and volume of radiotherapy (RT) - 30.6 Gy whole ventricular field and 54 Gy tumor-bed boost
Number of subjects: 107

Group type: COMPARATOR
Intervention: Full-dose craniospinal irradiation - 36 Gy craniospinal irradiation plus 54 Gy tumor-bed boost (used in ACNS0122)
Number of subjects: 107
Study: 31548190

Group type: EXPERIMENTAL
Intervention: Predicted fat mass
Number of subjects: 10251

Group type: EXPERIMENTAL
Intervention: Predicted lean body mass
Number of subjects: 10251
Study: 31548247

Group type: EXPERIMENTAL
Intervention: Medtronic 670G hybrid closed-loop system (Auto Mode)
Number of subjects: 79
Study: 31548342

Group type: EXPERIMENTAL
Intervention: PRC (PET Response Criteria)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: RECIST (Response Evaluation Criteria in Solid Tumors)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: PRC and RECIST
Number of subjects: 81
Study: 31548396

Group type: EXPERIMENTAL
Intervention: Exposure and ritual prevention (EX/RP)
Number of subjects: 0
Study: 31548621

Group type: EXPERIMENTAL
Intervention: Blood pressure-lowering treatment based on absolute cardiovascular risk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 0
Study: 31548863

Group type: EXPERIMENTAL
Intervention: Culturally relevant messaging for a social media campaign targeting tobacco cessation during pregnancy.
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Qualitative focus groups and individual interviews (Round 1)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Quantitative survey interviews (Round 2)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Strategies to manage stress and promote healthy pregnancy targets (e.g., prenatal care)
Number of subjects: 112
Study: 31549001

Group type: EXPERIMENTAL
Intervention: HBB Prompt mobile application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard HBB training without app access
Number of subjects: 10
Study: 31549155

Group type: EXPERIMENTAL
Intervention: 30-mg oral dose of primaquine (PQ)
Number of subjects: 550

Group type: COMPARATOR
Intervention: CYP2D6 genotypes
Number of subjects: 550
Study: 31549262

Group type: EXPERIMENTAL
Intervention: Bleeding risk scores (PARIS, PRECISE-DAPT, BleeMACS)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Frailty scales (Short Physical Performance Battery, Columbia, Edmonton, Clinical Frailty Scale)
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Combination of bleeding risk scores and frailty scales
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Bleeding risk scores and frailty scales
Number of subjects: 346
Study: 31549312

Group type: EXPERIMENTAL
Intervention: 40 IU/kg N9-GP
Number of subjects: 0
Study: 31549578

Group type: EXPERIMENTAL
Intervention: Facilitated data relay intervention during a 6-month phase.
Number of subjects: 2171

Group type: EXPERIMENTAL
Intervention: Facilitated data relay intervention
Number of subjects: 2171

Group type: COMPARATOR
Intervention: Phase A (status quo)
Number of subjects: 2171
Study: 31550265

Group type: EXPERIMENTAL
Intervention: BMI quartiles (higher BMI)
Number of subjects: 5964

Group type: EXPERIMENTAL
Intervention: WHtR quartiles (higher WHtR)
Number of subjects: 5964

Group type: EXPERIMENTAL
Intervention: Lean-fat group (low BMI <24.5 kg/m2 and high WHtR ≥0.55)
Number of subjects: 5964

Group type: EXPERIMENTAL
Intervention: HFpEF and HFrEF subtypes
Number of subjects: 5964
Study: 31550715

Group type: EXPERIMENTAL
Intervention: Ultrasound monitoring of guide-wire introduction during dialysis catheter insertion
Number of subjects: 30
Study: 31550737

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Wait and scan
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IDH-mutated glioma
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Miscellaneous rare LGGs
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: IDH wild-type WHO grade II or III glioma
Number of subjects: 100
Study: 31551193

Group type: EXPERIMENTAL
Intervention: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to 50 mg or 100 mg as needed.
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: SCTE-AI 75 mg once weekly for 6 weeks, adjusted to maintain T trough levels.
Number of subjects: 133
Study: 31551283

Group type: EXPERIMENTAL
Intervention: Noninvasive proportional assist ventilation (PAV)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Noninvasive pressure support ventilation (PSV)
Number of subjects: 15
Study: 31551349

Group type: EXPERIMENTAL
Intervention: 40 mg/kg OXi4503
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 10 mg/kg OXi4503
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 1 mg/kg OXi4503
Number of subjects: 2

Group type: COMPARATOR
Intervention: Sham dose
Number of subjects: 2
Study: 31551376

Group type: EXPERIMENTAL
Intervention: HCV Treatment as Prevention (TasP) in Tayside, Scotland
Number of subjects: 500

Group type: COMPARATOR
Intervention: Control sites in Scotland and England
Number of subjects: 500
Study: 31551805

Group type: EXPERIMENTAL
Intervention: Short-term high-intensity interval training (HIIT)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Long-term physical activity (PA)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Healthy active (HA)
Number of subjects: 147
Study: 31551824

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 31551902

Group type: EXPERIMENTAL
Intervention: Multidimensional management (MM) including psychoeducation and cognitive rehabilitation, n=34
Number of subjects: 221

Group type: COMPARATOR
Intervention: Control group with no specific treatment other than psychoeducation, n=46
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Favorable outcome (FO) group, n=101
Number of subjects: 221
Study: 31552171

Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with Pembrolizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31552422

Group type: EXPERIMENTAL
Intervention: Best practices for identifying and accounting for regression to the mean (RTM) in nutrition and obesity research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methods to quantify the degree of RTM
Number of subjects: 0
Study: 31552543

Group type: EXPERIMENTAL
Intervention: Bromfenac 0.07%
Number of subjects: 49

Group type: COMPARATOR
Intervention: Nepafenac 0.3%
Number of subjects: 49
Study: 31552588

Group type: EXPERIMENTAL
Intervention: Patients with 1-10 brain metastases (BM) before radiosurgery
Number of subjects: 92

Group type: COMPARATOR
Intervention: Controls (N=104)
Number of subjects: 92
Study: 31552641

Group type: EXPERIMENTAL
Intervention: Ipragliflozin 50-mg tablet once daily for 24 weeks
Number of subjects: 97
Study: 31552721

Group type: EXPERIMENTAL
Intervention: Capsaicin (lowest concentration causing 5 coughs or more, C5)
Number of subjects: 1882

Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 1882
Study: 31552762

Group type: EXPERIMENTAL
Intervention: Levels of oligomeric α-Synuclein in reflex tears
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 31553054

Group type: EXPERIMENTAL
Intervention: Weight-based dosing of avelumab (10 mg/kg)
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Flat dosing of avelumab (800 mg every 2 weeks)
Number of subjects: 1827
Study: 31553205

Group type: EXPERIMENTAL
Intervention: Intravascular lithotripsy (IVL)
Number of subjects: 120
Study: 31553429

Group type: EXPERIMENTAL
Intervention: 3DO body composition accuracy to DXA
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 3DO body fat test-retest precision
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 3DO visceral fat precision
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 3DO PCs correlation with serum markers
Number of subjects: 407

Group type: EXPERIMENTAL
Intervention: 3DO PCs prediction of isometric knee strength
Number of subjects: 407
Study: 31553487

Group type: EXPERIMENTAL
Intervention: Dasatinib at 50 mg daily
Number of subjects: 83
Study: 31553501

Group type: EXPERIMENTAL
Intervention: Sleep disturbance (self-reported poor or restless sleep)
Number of subjects: 319
Study: 31553639

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with three cycles of cisplatin.
Number of subjects: 111

Group type: COMPARATOR
Intervention: Induction chemotherapy (IC) with cisplatin and fluorouracil followed by concurrent chemoradiotherapy (CCR) with two cycles of cisplatin (amended treatment).
Number of subjects: 111

Group type: COMPARATOR
Intervention: Three cycles of cisplatin during CCR.
Number of subjects: 111
Study: 31553940

Group type: EXPERIMENTAL
Intervention: Bilateral caudate nucleus deep brain stimulation (DBS)
Number of subjects: 6
Study: 31554502

Group type: EXPERIMENTAL
Intervention: Good collateral status on mCTA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Intermediate collateral status on mCTA
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Poor collateral status on mCTA
Number of subjects: 65
Study: 31555109

Group type: EXPERIMENTAL
Intervention: tDCS (anodal; F3, cathodal, Fp2, 2A, 20 min) twice daily for five consecutive days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham-tDCS
Number of subjects: 20
Study: 31555382

Group type: EXPERIMENTAL
Intervention: High-FAR group (FAR > 8.713)
Number of subjects: 1352

Group type: EXPERIMENTAL
Intervention: Fibrinogen-to-albumin ratio (FAR)
Number of subjects: 1352

Group type: COMPARATOR
Intervention: Low-FAR group (FAR ≤ 8.713)
Number of subjects: 1352
Study: 31555487

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 12012

Group type: EXPERIMENTAL
Intervention: (Neo) adjuvant chemotherapy
Number of subjects: 12012

Group type: EXPERIMENTAL
Intervention: Adjuvant trastuzumab
Number of subjects: 12012

Group type: EXPERIMENTAL
Intervention: Adjuvant hormonotherapy
Number of subjects: 12012

Group type: EXPERIMENTAL
Intervention: Quality of life, psychological and behavioral outcomes
Number of subjects: 12012

Group type: EXPERIMENTAL
Intervention: Biologic sub-studies
Number of subjects: 12012
Study: 31555522

Group type: EXPERIMENTAL
Intervention: Apatinib (250 mg per day)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Apatinib
Number of subjects: 187
Study: 31555714

Group type: EXPERIMENTAL
Intervention: Autologous matrix-induced chondrogenesis (AMIC)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Autologous chondrocyte implantation (ACI-C)
Number of subjects: 41
Study: 31555795

Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 34

Group type: COMPARATOR
Intervention: N/A (comparison with control group HT)
Number of subjects: 34
Study: 31555815

Group type: EXPERIMENTAL
Intervention: Sleep duration and quality measured using a wrist-worn accelerometer and Pittsburgh Sleep Quality Index
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Personalized cold exposure to determine BAT volume, activity, and radiodensity
Number of subjects: 118
Study: 31556242

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) and Sleeve gastrectomy (SG)
Number of subjects: 29
Study: 31556778

Group type: EXPERIMENTAL
Intervention: Home pregnancy test A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home pregnancy test B
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home pregnancy test F
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home pregnancy test C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home pregnancy test E
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home pregnancy test D
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Home pregnancy test G
Number of subjects: 0
Study: 31557279

Group type: EXPERIMENTAL
Intervention: Crohn's disease participants
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy volunteers (HVs)
Number of subjects: 15
Study: 31557355

Group type: EXPERIMENTAL
Intervention: Intracutaneous Candida albicans antigen in participants with polyneuropathy
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intracutaneous Candida albicans antigen in healthy controls
Number of subjects: 41

Group type: COMPARATOR
Intervention: Intracutaneous Candida albicans antigen in participants without polyneuropathy
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Participants with diabetes
Number of subjects: 41
Study: 31557423

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in men at the operated knee
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in women at the operated knee
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in obese men at the operated knee
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in women at the nonoperated knee
Number of subjects: 272

Group type: EXPERIMENTAL
Intervention: Higher testosterone levels in obese women
Number of subjects: 272
Study: 31557500

Group type: EXPERIMENTAL
Intervention: Proximity to major roadways (within 100 m)
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Proximity to major roadways (greater than 100 m)
Number of subjects: 350
Study: 31558250

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0
Study: 31558366

Group type: EXPERIMENTAL
Intervention: Multidomain intervention plus omega-3 fatty acids
Number of subjects: 269

Group type: EXPERIMENTAL
Intervention: Multidomain intervention alone
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 31558424

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg orally once a day for 7 to 21 days preoperatively, resumed postoperatively in 28-day cycles.
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Neratinib (preoperative and postoperative administration).
Number of subjects: 5
Study: 31558447

Group type: EXPERIMENTAL
Intervention: Self-reported Somatic Symptom Scale-China (SSS-CN) questionnaire
Number of subjects: 852
Study: 31558467

Group type: EXPERIMENTAL
Intervention: Ublituximab (NHL: 900 mg; CLL: 600 or 900 mg) + Umbralisib (800 or 1200 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ublituximab + Umbralisib
Number of subjects: 0
Study: 31558469

Group type: EXPERIMENTAL
Intervention: GSI treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GSI treatment in MM tumor-bearing NOD/SCID/γc-/- mice
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Short-term GSI administration to MM patients
Number of subjects: 0
Study: 31558479

Group type: EXPERIMENTAL
Intervention: INVAC-1 (100, 400, and 800 μg) administered intradermally followed by electroporation or by Tropis, a needle-free injection system
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: INVAC-1
Number of subjects: 26
Study: 31558626

Group type: EXPERIMENTAL
Intervention: Lung cancer screening by low-dose computed tomography (LDCT)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: QRISK2 score assessment
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Statin primary prevention qualification (QRISK2≥10%)
Number of subjects: 680

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of predictors of statin use
Number of subjects: 680
Study: 31558670

Group type: EXPERIMENTAL
Intervention: ORH-2014 5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ORH-2014 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ORH-2014 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: ORH-2014
Number of subjects: 12
Study: 31558804

Group type: EXPERIMENTAL
Intervention: Ixazomib-thalidomide-dexamethasone (4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly) for eight cycles followed by ixazomib maintenance for one year
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ixazomib maintenance therapy
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Overall response rate, PFS, and OS
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Grade 3/4 toxicities
Number of subjects: 90
Study: 31559169

Group type: EXPERIMENTAL
Intervention: Radiomics strategy combined with clinical assessment (Peabody Developmental Motor Scales, MACS, HAI, AHA, GMFCS)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Internal and external validation of the radiomics model
Number of subjects: 130
Study: 31559605

Group type: EXPERIMENTAL
Intervention: Non-obese NASH patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Liver biopsy
Number of subjects: 84
Study: 31560055

Group type: EXPERIMENTAL
Intervention: Antiviral treatment (oseltamivir)
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Prior vaccination status
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Age (1-5 years)
Number of subjects: 2131

Group type: EXPERIMENTAL
Intervention: Resistance mutations
Number of subjects: 2131
Study: 31560741

Group type: EXPERIMENTAL
Intervention: E/C/F/TAF (150/150/200/10 mg once daily)
Number of subjects: 9

Group type: COMPARATOR
Intervention: E/C/F/TDF (150/150/200/300 mg once daily)
Number of subjects: 9
Study: 31560765

Group type: EXPERIMENTAL
Intervention: Mesopic testing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dark-adapted (DA) cyan testing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Dark-adapted (DA) red testing
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Presence of a residual outer nuclear layer
Number of subjects: 36
Study: 31560935

Group type: EXPERIMENTAL
Intervention: SM08502 (CLK inhibitor), orally administered
Number of subjects: 0